Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;9(2):215-26.
doi: 10.31887/DCNS.2007.9.2/jbobes.

Quality of life in schizophrenic patients

Julio Bobes  1 , Maria Paz Garcia-Portilla, Maria Teresa Bascaran, Pilar Alejandra Saiz, Manuel Bousoño
Affiliations
Review

Quality of life in schizophrenic patients

Julio Bobes et al. Dialogues Clin Neurosci. 2007.

Abstract
in English, Spanish, French

In the last decades, there has been increased interest in the field of quality of life in mental disorders in general, and particularly in schizophrenia. In addition, the appearance of the atypical antipsychotic drugs (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone) with different therapeutic and side-effect profiles, has promoted a greater interest in assessing the quality of life of schizophrenic patients. In this paper we will briefly summarize the difficulties in assessing quality of life in schizophrenic patients, as well as the results concerning their quality of life and the influence of psychopathology, especially negative and depressive symptoms, on it. We will also review data from recent clinical trials showing the impact ofantipsychotic treatments and their side effects upon quality of life.

Durante las últimas décadas se ha producido un creciente interés en el campo de la calidad de vida en los trastornos mentales en general, y en la esquizofrenia en particular. Por otra parte, la aparición de los medicamentos antipsicóticos atípleos (amilsupríde, aripiprazol, clozapina, olanzapina, quetiapina, risperidona y ziprasidona) con diferentes perfiles terapéuticos y efectos secundarios, ha promovido un mayor interés a la hora de evaluar la calidad de vida en los pacientes que padecen esquizofrenia. En este trabajo se analizan brevemente las dificultades que conlleva la evaluación de la calidad de vida en pacientes con esquizofrenia además de los resultados acerca de su calidad de vida y la influencia de psicopatología, especialmente síntomas negativos y depresivos, sobre ésta. También se revisan resultados de ensayos clínicos recientes que muestran el impacto del tratamiento antipsicótico y de sus efectos secundarios sobre la calidad de vida.

L'intérêt pour la qualité de vie au cours des troubles mentaux en général et de la schizophrénie en particulier s'est accru ces 10 dernières années. L'émergence de médicaments antipsychotiques atypiques (amisulpride, aripiprazole, cloza-pine, olanzapine, quétiapine, rispéridone et zipra-sidone) dotés de profils d'effets thérapeutiques et d'effets secondaires différents a favorisé l'intérêt croissant dans l'évaluation de la qualité de vie des patients schizophrènes. Nous allons rapidement résumer dans cet article les difficultés d'évaluation de la qualité de vie des patients schizophrènes, ainsi que les résultats de la qualité de vie et l'influence de la psychopathologie sur celle-ci, en particulier les symptômes dépressifs et négatifs. Nous allons aussi revoir des données d'études cliniques récentes qui montrent l'impact des traitements antipsychotiques et leurs effets indésirables sur la qualité de vie.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Outcomes in schizophrenia. Modified from reference 12: Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quai Life Res. 1997;6:21-26. Copyright © Kluwer Academic Publishers 1997.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. The WHOQOL Group. The World Health Organization Quality of Life Assessment (the WHOQOL): position paper from the World Health Organisation. Soc Sci Med. 1995;41:1403–1409. - PubMed
    1. Bobes J., Garcia-Portilla MP. Quality of life in schizophrenia. In: Katschnig H, Freeman H, Sartorius N, eds. Quality of Life in Mental Disorders. Chichester, UK: John Wiley & Sons Ltd; 2005:153–168.
    1. Bobes J. Current status of quality of life assessment in schizophrenic patients. Eur Arch Psychiatry Clin Neurosc. 2001;251(suppl 2):ll/38–ll/42. - PubMed
    1. Bobes J., Garcia-Portilla MP., Saiz PA., Bascaran T., Bousoño M. Quality of life measures in schizophrenia. Eur Psychiatry. 2005;20:5313–5317. - PubMed
    1. Lehman AF., Postrado LT., Rachoba LT. Convergent validation of quality of life assessment for persons with severe mental illness. Qual Life Res. 1993;2:327–333. - PubMed

MeSH terms

Substances